Britain’s health ministry announced Tuesday that it will expand access to Pfizer’s PFE.N oral antiviral COVID-19 therapy to thousands more individuals by enrolling them in a trial evaluating the drug’s optimal usage in its highly vaccinated population. People with weakened immune systems in the United Kingdom can now use Paxlovid, which combines Pfizer’s new tablet with an older antiviral drug